tovaxin

an autologous attenuated T-cell vaccine

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Multiple Sclerosis 07/01/2011 - "Tovaxin for multiple sclerosis." 05/01/2008 - "Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis." 07/01/2011 - "A potential therapeutic possibility for multiple sclerosis (MS) is provided by Tovaxin, a personalized autologous T-cell immunotherapy utilizing myelin-reactive lymphocytes from peripheral blood. " 05/01/2008 - "Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. "
2.	Relapsing-Remitting Multiple Sclerosis 05/01/2009 - "Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies."
3.	Rheumatoid Arthritis 05/01/2008 - "Opexa was previously investigating Tovaxin for the potential treatment of rheumatoid arthritis; however, no development has been reported for this indication since December 2002."